Cell therapy enabling safe haploidentical haematopoietic stem cell transplantation (HSCT) for the treatment of haematological malignancies. Phase III in high-risk acute leukaemia started in Italy
A novel VTA for vascularised solid tumours. Phase II trials as single agent ongoing in colorectal and liver cancer, and in mesothelioma. Phase II trials in combination ongoin with Xelox in colorectal cancer, and with doxorubicin in small-cell lung and ovarian cancer




Jul 2, 2009
Results of Phase I of NGR-hTNF in combination with doxorubicin published by the British Journal of Cancer


Jun 1, 2009
Clinical update of NGR-hTNF presented at ASCO 2009: Top-line results of Phase II trial in mesothelioma - Combination with cisplatin entering Phase II in lung cancer - Long-term data of Phase II trial in colorectal cancer - Interim update of Phase II trial in liver cancer


May 20, 2009
Updated company presentation delivered at BIO 2009


May 11, 2009
MolMed Board of Directors approves the financial report for the first quarter of year 2009


more news